Fjarde AP Fonden Fourth Swedish National Pension Fund Purchases 6,200 Shares of Edwards Lifesciences Corporation $EW

Key Points

• The Fjarde AP Fonden Fourth Swedish National Pension Fund increased its stake in Edwards Lifesciences Corporation by 5.6%, now holding 117,666 shares valued at approximately $8.5 million after purchasing an additional 6,200 shares.
• Insider sales include Larry L. Wood selling 8,950 shares, and VP Daveen Chopra selling 1,500 shares, indicating a decrease in their ownership of the company's stock.
• Recent analysts' target price adjustments include Evercore ISI raising the target from $77 to $80, and Wells Fargo increasing it from $84 to $88, contributing to a consensus price target of $85.90.

Fjarde AP Fonden Fourth Swedish National Pension Fund raised its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 5.6% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 117,666 shares of the medical research company's stock after acquiring an additional 6,200 shares during the quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund's holdings in Edwards Lifesciences were worth $8,528,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. Jennison Associates LLC grew its stake in Edwards Lifesciences by 34.3% during the 1st quarter. Jennison Associates LLC now owns 10,086,033 shares of the medical research company's stock valued at $731,036,000 after acquiring an additional 2,576,383 shares in the last quarter. Brown Advisory Inc. grew its stake in shares of Edwards Lifesciences by 7.6% in the 4th quarter. Brown Advisory Inc. now owns 8,155,355 shares of the medical research company's stock valued at $603,741,000 after buying an additional 575,699 shares in the last quarter. Deutsche Bank AG grew its stake in shares of Edwards Lifesciences by 10.4% in the 4th quarter. Deutsche Bank AG now owns 6,903,202 shares of the medical research company's stock valued at $511,044,000 after buying an additional 652,923 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of Edwards Lifesciences by 8.5% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 6,519,257 shares of the medical research company's stock valued at $482,621,000 after buying an additional 513,468 shares in the last quarter. Finally, Northern Trust Corp grew its stake in shares of Edwards Lifesciences by 21.8% in the 4th quarter. Northern Trust Corp now owns 6,505,227 shares of the medical research company's stock valued at $481,582,000 after buying an additional 1,165,845 shares in the last quarter. Hedge funds and other institutional investors own 79.46% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages recently commented on EW. The Goldman Sachs Group reissued a "buy" rating on shares of Edwards Lifesciences in a research note on Friday, July 25th. Evercore ISI boosted their price target on Edwards Lifesciences from $77.00 to $80.00 and gave the company an "in-line" rating in a research note on Friday, July 25th. BTIG Research upgraded Edwards Lifesciences from a "neutral" rating to a "buy" rating and set a $100.00 target price for the company in a report on Tuesday, July 29th. Barclays boosted their target price on Edwards Lifesciences from $90.00 to $95.00 and gave the stock an "overweight" rating in a report on Friday, July 25th. Finally, Wall Street Zen upgraded Edwards Lifesciences from a "hold" rating to a "buy" rating in a report on Saturday, July 26th. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $85.90.

Edwards Lifesciences Trading Up 3.0%

Shares of EW traded up $2.3440 during trading hours on Wednesday, hitting $81.2740. 5,058,602 shares of the stock traded hands, compared to its average volume of 4,834,787. The company has a current ratio of 4.68, a quick ratio of 3.87 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a 1-year low of $64.00 and a 1-year high of $83.00. The firm has a market capitalization of $47.72 billion, a PE ratio of 11.69, a price-to-earnings-growth ratio of 3.81 and a beta of 1.08. The business has a fifty day moving average of $77.35 and a 200-day moving average of $74.54.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.62 by $0.05. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The business had revenue of $1.53 billion for the quarter, compared to analyst estimates of $1.49 billion. During the same quarter in the prior year, the firm posted $0.70 earnings per share. The firm's revenue for the quarter was up 11.9% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. Analysts expect that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Insider Buying and Selling

In other Edwards Lifesciences news, insider Larry L. Wood sold 8,950 shares of the stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $75.23, for a total value of $673,308.50. Following the transaction, the insider owned 206,900 shares of the company's stock, valued at approximately $15,565,087. This represents a 4.15% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP Daveen Chopra sold 1,500 shares of the stock in a transaction dated Thursday, May 22nd. The shares were sold at an average price of $75.08, for a total value of $112,620.00. Following the completion of the transaction, the vice president directly owned 33,496 shares in the company, valued at $2,514,879.68. The trade was a 4.29% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 26,084 shares of company stock worth $2,010,382. Corporate insiders own 1.29% of the company's stock.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.